Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Merck & Co. patents LRKK2-mutant inhibitors

May 8, 2019

Pilot study of L1-79 demonstrates trends towards improvement in male subjects with ASD

May 8, 2019

FDA clears IND application for NNI-362

May 8, 2019

FDA approves Ruzurgi for pediatric patients with Lambert-Eaton myasthenic syndrome

May 7, 2019

Phase III trial of Epidiolex in TSC meets primary endpoint

May 7, 2019

Axsome announces expedited development and pivotal status for AXS-05 for the treatment of MDD

May 7, 2019

Skyhawk and Takeda collaborate to develop small-molecule treatments for neurodegenerative diseases

May 7, 2019

Esteve Pharmaceuticals presents new analgesics

May 7, 2019

Huntington's hopefuls present at AAN 2019

May 7, 2019

Targeting metabolism prevents epilepsy after TBI

May 7, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 26, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
Dual-targeting, rapamycin-enhanced CAR T for multiple myeloma
BioWorld Science
Umoja Biopharma Inc. performed preclinical studies to evaluate the antitumor activity of UB-VV500, an off-the-shell lentiviral vector CAR T-cell product. It is...